Lifeboat Foundation

In a recent presentation, Tesla said that it was working to eliminate rare Earth magnets from its EVs over supply and toxicity concerns.

In a major move, Tesla is looking to rid its electric vehicles of rare Earth minerals, potentially eliminating the biggest environmental concern over the increasing number of EVs on the road.

The surprise announcement came during Tesla’s Master Plan 3 Investor event where the company outlined its business strategy for the next few years.

Continue reading “Elon Musk says he’s getting rid of rare Earth magnets in Tesla EVs” »

Xtekky, a European computer science student, finds out what happens if you write a program that runs queries through these freely accessible sites and returns you the answer.

In other news, a big company with a non-profit and for-profit subsidiary sues an independent creator trying to make things easier for everyday folks. Even though it technically doesn’t violate its terms and conditions? Perhaps we’ll leave that for the experts to decide.

OpenAI, the creators of ChatGPT, a scourge on teachers and succor to everyone else, opted against free access when it released its newer GPT4 model.

This is an important step on the way to develop brain–computer interfaces that can decode continuous language through non-invasive recordings of thoughts.

Results were published in a recent study in the peer-reviewed journal Nature Neuroscience, led by Jerry Tang, a doctoral student in computer science, and Alex Huth, an assistant professor of neuroscience and computer science at UT Austin.

Tang and Huth’s semantic decoder isn’t implanted in the brain directly; instead, it uses fMRI machine scans to measure brain activity. For the study, participants in the experiment listened to podcasts while the AI attempted to transcribe their thoughts into text.

Scientists are still determining whether humans will reach a maximum possible age or if we can extend lifespan indefinitely. One thing we know is that the aging we see and feel in our bodies is connected to aging that individual cells experience. Yeast is a common model in molecular biology that is often used to study aging. In 2020, scientists found that yeast cells could go down one of two aging paths; in one, structures called nucleoli were degraded and ribosomal DNA experienced less silencing; in the other, mitochondria were affected and heme accumulation was reduced. The researchers suggested that these were two distinct types of terminal aging.

In follow-up work, the research team has manipulated the genetics of those pathways, and have extended the lifespan of cells by doing so. The work has been reported in Science. The investigators applied a solution to the cells that altered gene circuits to stop the cells from deteriorating.

IBM chief executive Arvind Krishna said the company expects to pause hiring for roles it thinks could be replaced with artificial intelligence in the coming years.

This scientist made an algorithm to predict which artists succeed–without even looking at their art.

This is the latest episode of the free DDW narrated podcast, “The impact of technology on drug discovery”. It covers two articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Talking Tech” and “Rejuvenation biotech: Can this company make age a thing of the past?”

With Covid-19 taking so much of the drug discovery and development’s focus over the last two years, it has been easy to overlook other areas within the sector that deserve our attention. So in the first article, Lu Rahman highlights the technology that will play a valuable role in the industry.

Kizoo Technology Capital has a clear aim – to develop drugs that abate or cure age-related diseases. In the second article, Lu Rahman spoke to owner, Michael Greve, to find out more about this exciting work that aims to make age-related therapies affordable for everyone.

“There are patients with localized prostate cancer who undergo prostatectomy or radiation therapy in an attempt to cure their disease, but, unfortunately, some patients will develop BCR,” said Neal Shore, M.D., F.A.C.S., U.S. Chief Medical Officer of Urology and Surgical Oncology, GenesisCare, Director, Carolina Urologic Research Center, and Primary Investigator for the EMBARK study. “Importantly, some patients with BCR are at very high risk for developing metastatic disease, which can lead to a cascade of therapeutic interventions. The clinical goal of BCR therapy is to delay cancer progression and avoid metastatic disease. The MFS results from the EMBARK study demonstrate that this intervention with XTANDI plus leuprolide was statistically significant for patients with high-risk BCR.”

“The EMBARK study is a Phase 3 trial exploring the potential of enzalutamide in patients with non-metastatic hormone-sensitive prostate cancer with high-risk BCR,” said Stephen J. Freedland, M.D., Director of the Center for Integrated Research in Cancer and Lifestyle and the Warschaw Robertson Law Families Chair in Prostate Cancer at Cedars-Sinai Cancer and Co-Principal Investigator of the Clinical Trial. “If approved, we hope to bring a new option to men earlier in the course of their disease.”

Consistent with the study’s primary endpoint, statistically significant and clinically meaningful improvements were also observed in the trial’s key secondary endpoints in both the XTANDI combination and monotherapy arms. Specifically, the XTANDI monotherapy arm demonstrated that treatment with XTANDI reduced the risk of metastasis or death by 37% versus leuprolide plus placebo (HR: 0.63; 95% CI, 0.46–0.87; P=0.0049), meeting its MFS endpoint. Treatment with XTANDI plus leuprolide and XTANDI monotherapy reduced the risk of PSA progression by 93% (HR: 0.07; 95% CI, 0.03–0.14; P0.0001) and 67% (HR: 0.33; 95% CI, 0.23–0.49; P0.0001), respectively, versus placebo plus leuprolide. The progression risk in starting a new antineoplastic therapy was reduced by 64% in those treated with XTANDI plus leuprolide (HR: 0.36; 95% CI, 0.26–0.49; P0.0001) and 46% in those treated with XTANDI monotherapy (HR: 0.54; 95% CI, 0.41–0.71; P0.0001) versus placebo plus leuprolide.

We’re not in favor of any jobs going solely to robots. But if any jobs should be automated, it should probably be those of the CEOs.